Phosphate binder use, by DOPPS country and cross-section |
N Ptnts | Wgtd % | Total N | ||
---|---|---|---|---|
DOPPS Country | DOPPS Cross-section | 7,354 | 80.6% | 9,117 |
All | DOPPS 2(2002) | |||
DOPPS 3(2006) | 7,213 | 84.3% | 8,552 | |
DOPPS 3(2007) | 6,441 | 83.6% | 7,672 | |
AusNZ | DOPPS 2(2002) | 452 | 88.9% | 513 |
DOPPS 3(2006) | 465 | 88.2% | 527 | |
DOPPS 3(2007) | 440 | 90.8% | 486 | |
Belgium | DOPPS 2(2002) | 478 | 88.7% | 538 |
DOPPS 3(2006) | 428 | 83.1% | 509 | |
DOPPS 3(2007) | 346 | 82.2% | 420 | |
Canada | DOPPS 2(2002) | 543 | 90.9% | 601 |
DOPPS 3(2006) | 501 | 91.2% | 551 | |
DOPPS 3(2007) | 409 | 90.5% | 445 | |
France | DOPPS 2(2002) | 399 | 75.4% | 528 |
DOPPS 3(2006) | 437 | 79.6% | 551 | |
DOPPS 3(2007) | 448 | 81.4% | 543 | |
Germany | DOPPS 2(2002) | 422 | 74.4% | 571 |
DOPPS 3(2006) | 478 | 82.1% | 583 | |
DOPPS 3(2007) | 522 | 82.8% | 623 | |
Italy | DOPPS 2(2002) | 443 | 76.7% | 576 |
DOPPS 3(2006) | 409 | 76.6% | 533 | |
DOPPS 3(2007) | 438 | 80.1% | 542 | |
Japan | DOPPS 2(2002) | 1,382 | 76.5% | 1,805 |
DOPPS 3(2006) | 1,562 | 85.1% | 1,832 | |
DOPPS 3(2007) | 1,520 | 81.3% | 1,867 | |
Spain | DOPPS 2(2002) | 553 | 90.0% | 613 |
DOPPS 3(2006) | 573 | 86.0% | 666 | |
DOPPS 3(2007) | 460 | 82.7% | 555 | |
Sweden | DOPPS 2(2002) | 433 | 79.2% | 547 |
DOPPS 3(2006) | 464 | 85.4% | 542 | |
DOPPS 3(2007) | 453 | 88.6% | 511 | |
UK | DOPPS 2(2002) | 359 | 63.0% | 565 |
DOPPS 3(2006) | 342 | 76.4% | 445 | |
DOPPS 3(2007) | 272 | 76.6% | 351 | |
US | DOPPS 2(2002) | 1,890 | 83.5% | 2,260 |
DOPPS 3(2006) | 1,554 | 85.9% | 1,813 | |
DOPPS 3(2007) | 1,133 | 84.8% | 1,329 |
Percent of patients prescribed any phosphate binder in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.